UCLA Campus    |   UCLA Health    |   School of Medicine Translate:
Back to Urology at UCLA home It Begins With U

Urology at UCLA

Print
Email
Share

Kidney Cancer Doctors

IUO
Phone: (310) 794-7700

Appointment Request Form

Kidney Cancer Doctors, Los Angeles, CA

The Department of Urology at UCLA is one of the oldest, most progressive and comprehensive urology programs in the country. Our renowned faculty members in Male Urology work side by side with research scientists in the quest for new cures and treatments for kidney cancer. Our fellowship programs for specialists in urology are the models used by many medical schools and our graduates are now managing urology fellowship programs around the globe.

 
Arie Belldegrun, MD, FACS
Arie Belldegrun, MD, FACS
Director of the Institute of Urologic Oncology (www.iuo.ucla.edu); Professor of Urology; Chief, Division of Urologic Oncology; Founder and Surgical Director, UCLA Kidney Cancer Program (www.kidneycancer.ucla.edu). Dr. Belldegrun also holds the Roy and Carol Doumani Chair in Urologic Oncology and serves as the Director of the Urologic Oncology Fellowship Program at UCLA. His surgical expertise encompasses all aspects of urologic oncology, including kidney cancer, prostate cancer, bladder cancer and testicular cancer. He has authored over 400 peer-reviewed publications, books, and book chapters in the area of localized and advanced kidney and prostate cancer. Dr. Belldegrun is a world-renown expert in complicated kidney cancer surgeries, and has unique expertise in a variety of surgical approaches to small kidney tumors including open, laparoscopic, and robotic partial nephrectomy and cryotherapy. He is also a recognized expert in minimally invasive and focal prostate cancer therapy, specifically cryo-surgical prostate cancer ablation, and has published extensively his UCLA experience with cryotherapy. Dr. Belldegrun's research lab at UCLA focuses on the development of personalized cancer immunotherapy and targeted cancer vaccines for the treatment of kidney cancer.
 
Karim Chamie, MD, MSHS
Karim Chamie, MD, MSHS
Assistant Professor-in-Residence of Urology. He attended Medical School at USC and completed Urological training at UC Davis. Dr. Chamie then completed a SUO certified fellowship in Urologic Oncology at UCLA. His primary research interests are health services research and clinical trials in bladder cancer. His clinical interests include all areas of urologic oncology, with a particular emphasis on bladder cancer and robotic surgery.
 
Arnold I. Chin, MD, PhD
Arnold I. Chin, MD, PhD
Assistant Professor of Urology. Dr. Chin completed his M.D., Ph.D. and Urology residency training at UCLA. His clinical expertise includes urologic oncology and renal transplantation, with a focus on bladder cancer. He performs open, laparoscopic, and robotic-assisted surgeries for bladder, kidney, and prostate cancer patients. Dr. Chin's laboratory in the Broad Stem Cell Research Institute studies the tumor microenvironment in prostate and bladder cancer in efforts to develop novel immune and stem cell-based therapies against cancer.
 
Jean B. DeKernion, MD
Jean B. DeKernion, MD
Professor Emeritus of Urology. Residency, Case Western Reserve in Cleveland, fellowship, National Cancer Institute. Certified by the American Board of Surgery and American Board of Urology. World leader in Urologic Oncology, co-authored the first textbook on the subject. Founder, Society of Urologic Oncology, member of the American Board of Urology, Chair, Department of Defense prostate cancer Research program. Kidney, bladder and prostate cancer are the areas in which he has made the most significant contributions.
 
Fairooz Kabbinavar, MD, FACP
Fairooz Kabbinavar, MD, FACP
Affiliated Programs: Kidney Cancer, Urologic Oncology
Professor of Medicine and Urologic Oncology, Medical Director of UCLA Kidney Cancer Program and Henry Alvin and Carrie L. Meinhardt endowed chair in Kidney cancer research. Dr. Fairooz Kabbinavar received his B.Sc., M.B.B.S. and M.D. degrees from Nagpur University in India. In UCLA's Division of Hematology/Oncology, he did his postdoctoral research fellowship and a clinical Hematology-Oncology fellowship, with his internship and residency at Beth Israel Hospital at Harvard University in Boston. Dr.Kabbinavar's research interests are in anti-angiogenic and novel targeted therapeutics. His work was responsible for the FDA approval of Bevacizumab.
 
Mark S. Litwin, MD, MPH
Mark S. Litwin, MD, MPH
Chair, Department of Urology. Professor of Urology and Public Health. He trained at Harvard and specializes in testicular, bladder, prostate and kidney cancer. Dr. Litwin’s research focuses on improving quality of care and quality of life in urologic oncology. He leads Urologic Diseases in America (www.udaonline.net), the NIH’s largest effort at documenting the burden of urologic diseases on the American people. He also created and directs IMPACT, a state-funded program that provides free medical care statewide for low-income, uninsured men with prostate cancer (www.california-impact.org).
 
Allan Pantuck, MD, MS, FACS
Allan Pantuck, MD, MS, FACS
Professor of Urology, Dr. Pantuck specializes in urologic cancers and has a long standing interest in kidney, prostate, bladder cancers, developing new treatment strategies through basic and clinical research and in the study of nutritional approaches to their prevention and treatment.
 
Steven Raman, MD
Steven Raman, MD
Dr. Steven Raman is a Professor of Radiology and Urology and is an expert in Urological Radiology, having published over 75 papers, 100 abstracts and several book chapters in this field. He has been the founding member of the UCLA Prostate Imaging Group, whose members include physicians and scientists dedicated to advancing the field of prostate imaging. Dr. Raman believes that MR imaging the best non-invasive solution for finding the most aggressive prostate cancer.
 
Robert E. Reiter, MD
Robert E. Reiter, MD
Professor, Urology, Molecular Biology, Director of the Prostate Cancer Program, Director of Urologic Research, Co-Director of the Genitourinary Oncology Program in UCLA's Jonsson Cancer Center. Attended Stanford Medical School, completed urologic training at Stanford and Baylor College of Medicine, completed additional fellowship training in urological cancer at the National Cancer Institute. His clinical interests include all areas of urologic oncology, with an emphasis on prostate cancer. He specializes in robotically-assisted prostatectomy and cystectomy, as well as open surgery, with robotic experience dating back to 2004, for bladder, prostate, and renal malignancies. Dr. Reiter is involved in all aspects of urologic oncology, with an emphasis on prostate cancer, and brings extensive experience in robotic surgery and the applications of translational research and the latest in MRI and molecular imaging to the management of men with this disease.
 
Christopher Saigal, MD, MPH
Christopher Saigal, MD, MPH
Professor and Vice Chair, Urology. Clinical practice, UCLA Westwood Campus. He is also on the staff of the West Los Angeles Veterans Affairs Medical Center. Dr. Saigal has had a longstanding clinical interest in urologic cancers and the surgical treatment of benign prostatic hyperplasia. His research is focused on patient-centered decision support and quality of care for urologic conditions.
 
Robert B. Smith, MD
Robert B. Smith, MD
Professor, Urology. Faculty member, completed UCLA residency, 1969. Assistant Professor of Urology, Chief of the Renal Transplant service. Associated Professor of Urology / Professor of Urology. Served in the Air Force, Lieutenant Colonel, Chief of Urology, Lackland Air Force Base. Vice-Chairman, Urology, Chief of Staff, UCLA Medical Center. Director, Urology residency training. His clinical interests are in the treatment of urologic malignancies, and in reconstructive urologic cases.
 
UCLA Rated One of the Top Hospitals in the Nation